Busca avançada
Ano de início
Entree


The SGLT2 Inhibitor Empagliflozin Mitigates the Harmful Effects of Methylglyoxal Exposure on Ovalbumin-Induced Mouse Airway Inflammation

Texto completo
Autor(es):
Medeiros, Matheus L. ; Oliveira, Akila L. ; Antunes, Edson
Número total de Autores: 3
Tipo de documento: Artigo Científico
Fonte: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 26, n. 12, p. 19-pg., 2025-06-16.
Resumo

Asthma is a chronic inflammatory airway disease that can be aggravated by metabolic comorbidities such as type 2 diabetes mellitus (DM2) and obesity. Elevated levels of methylglyoxal (MGO), a reactive glycolysis byproduct, have been associated with exacerbation of allergic airway disease. SGLT2 inhibitors have been successfully employed in DM2 treatment. Here, we hypothesized that elimination of MGO might be a potential anti-inflammatory mechanism of SGLT2 inhibitors. This study aimed to evaluate the effects of empagliflozin on ovalbumin (OVA)-induced airway inflammation in mice chronically exposed to MGO. Male C57BL/6 mice sensitized with OVA were exposed to 0.5% MGO for 12 weeks and treated with empagliflozin (10 mg/kg, gavage, two weeks). MGO exposure significantly enhanced airway eosinophil infiltration, mucus production and collagen deposition, as well as levels of IL-4, IL-5, eotaxin and TNF-alpha. Empagliflozin treatment significantly reduced OVA-induced airway disease, which was accompanied by reductions in IgE, IL-4, IL-5, eotaxin, and TNF-alpha levels. Empagliflozin significantly reduced the MGO levels in serum, and immunohistochemical staining, and protein expression of MGO-hydroimidazolone (MG-H1), while increasing IL-10 levels and glyoxylase-1 (GLO 1) activity in lungs. In conclusion, empagliflozin efficiently removes MGO from circulation, while increasing the MGO detoxification by GLO 1, thereby mitigating the OVA-induced inflammation in MGO-exposed mice. (AU)

Processo FAPESP: 24/10306-4 - Eixo metilglioxal - produtos finais de glicação avançada (AGEs) - receptor para AGEs (AGEr): Potencial alvo terapêutico para prevenção e tratamento da disfunção vesical associada a obesidade e diabetes
Beneficiário:Edson Antunes
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 24/03508-0 - Obesidade e asma: papel do metilglioxal e produtos finais de glicação avançada na resposta inflamatória pulmonar alérgica em camundongos geneticamente obesos
Beneficiário:Matheus Leite de Medeiros
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado